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BACKGROUND: Surveillance, Epidemiology, and End Results (SEER) registry data have been used to suggest under-
use and disparities in receipt of radiotherapy. Prior studies have cautioned that SEER may underascertain radiother-
apy but lacked adequate representation to assess whether underascertainment varies by geography or patient
sociodemographic characteristics. The authors sought to determine rates and correlates of underascertainment of
radiotherapy in recent SEER data. METHODS: The authors evaluated data from 2290 survey respondents with non-
metastatic breast cancer, aged 20 to 79 years, diagnosed from June of 2005 to February 2007 in Detroit and Los
Angeles and reported to SEER registries (73% response rate). Survey responses regarding treatment and sociodemo-
graphic factors were merged with SEER data. The authors compared radiotherapy receipt as reported by patients
versus SEER records. The authors then assessed correlates of radiotherapy underascertainment in SEER. RESULTS:
Of 1292 patients who reported receiving radiotherapy, 273 were coded as not receiving radiotherapy in SEER (under-
ascertained). Underascertainment was more common in Los Angeles than in Detroit (32.0% vs 11.25%, P < .001). On
multivariate analysis, radiotherapy underascertainment was significantly associated in each registry (Los Angeles, Detroit)
with stage (P ¼ .008, P ¼ .026), income (P < .001, P ¼ .050), mastectomy receipt (P < .001, P < .001), chemotherapy
receipt (P < .001, P ¼ .045), and diagnosis at a hospital that was not accredited by the American College of Surgeons (P
< .001, P < .001). In Los Angeles, additional significant variables included younger age (P < .001), nonprivate insurance (P
< .001), and delayed receipt of radiotherapy (P < .001). CONCLUSIONS: SEER registry data as currently collected may
not be an appropriate source for documentation of rates of radiotherapy receipt or investigation of geographic varia-
tion in the radiation treatment of breast cancer. Cancer 2012;118:333–41. VC 2011 American Cancer Society.
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The National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program began collecting cancer
registry data in 1973. Currently, SEER collects data from regional cancer registries that cover 26% of the US population.1
These data include information on cancer incidence, patient demographics, clinical and treatment factors, and survival,
information of considerable relevance to those pursuing the agenda for comparative effectiveness research in health care.
SEER data have been used to answer a variety of research questions.2 Several influential studies have relied upon
SEER data alone to determine the appropriateness of care delivered to breast cancer patients, including rates of receipt
of radiotherapy (RT) after breast-conserving surgery (BCS).3,4 These studies have suggested underuse of RT as well as
disparities in use by race, age, and geography.
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The SEER program issues a standardized coding
manual that indicates that all treatments administered as
part of the first course (which is defined in detail in the
manual and is no longer limited to a 4-month period of
time) are to be considered for the radiation treatment
summary field.5 However, some studies have suggested
that registry data may be incomplete, particularly for
treatments like RT that may be delivered in the outpatient
setting.6,7 These studies have led to some increased
caution in the use of SEER data alone, but have not con-
vinced researchers to abandon publishing studies of RT
use based on analyses of SEER data alone,8-10 nor even
always to acknowledge potential limitations. Further-
more, existing studies assessing the adequacy of ascertain-
ment of treatments in SEER registry data have lacked
adequate sample diversity by race, age, and geography to
assess whether ascertainment varies by these subgroups. In
addition, rates of RT underascertainment may have risen
in recent years, with increasing use of chemotherapy
before RT leading to the delay of RT beyond a time
period readily ascertained by registrars.
In light of these gaps in the literature, we conducted
a study comparing SEER data on RT receipt from 2 large
regional registries to self-report by patients recently
treated for breast cancer to answer 3 questions. First, how
well do these SEER registries ascertain RT receipt in the
current era; second, do different SEER sites differ in rates
of RT ascertainment; and third, if RT underascertainment
exists, does it vary systematically by clinical or sociodemo-
graphic factors?
MATERIALS AND METHODS
Sampling and Data Collection
Details of the study design have been published else-
where.11-13 Women in the metropolitan areas of Los
Angeles and Detroit aged 21 to 79 years, diagnosed with
stage 0 to 314 primary ductal carcinoma in situ or invasive
breast cancer from June 2005 through February 2007
were eligible for sample selection. Latina (in Los Angeles)
and African American (in both Los Angeles and Detroit)
patients were oversampled.
Eligible patients were selected using rapid case ascer-
tainment as they were reported to the Los Angeles Cancer
Surveillance Program and the Metropolitan Detroit
Cancer Surveillance System-SEER program registries.
This method was used to obtain a representative sample of
cases sooner after diagnosis than can be provided by rou-
tine ascertainment. We selected all African Americans in
both sites and all Hispanic patients in Los Angeles
followed by a random sample of non-African American/
non-Hispanic patients in both regions to achieve the
target sample size.12 Asian women in Los Angeles were
excluded because these women were being enrolled in
other studies.
Physicians were notified of our intent to contact
patients, followed by a patient mailing of survey materials
and $10 to eligible subjects. The questionnaire was trans-
lated into Spanish,15 and the Dillman method was used to
encourage response.16 The protocol was approved by the
institutional review boards of the University of Michigan,
University of Southern California, and Wayne State
University.
We accrued 3252 eligible patients, including
approximately 70% of Latina and African American
patients and 30% of non-Latina white patients diagnosed
in Los Angeles and Detroit during the study period. After
initial selection, another 119 were excluded because 1)
physician refused permission to contact (n ¼ 20); 2)
patient did not speak English or Spanish (n ¼ 17); 3)
patient was too ill or incompetent to participate (n¼ 59);
and 4) patient denied having cancer (n ¼ 23). Of the
3133 eligible patients included in the final accrued sam-
ple, 2290 (73.1%) completed surveys, and 2268 (72.4%)
were later able to be matched to quality-controlled inci-
dent cases ascertained by the SEER registries. On average,
patients were surveyed 10 months after diagnosis.
As shown in Figure 1, 2179 patients responded to a
question asking whether they had received or planned to
receive RT. We excluded the 237 patients who indicated
that they had yet to begin RT at the time of the survey; we
also excluded the 15 patients missing SEER data on RT
receipt, leaving 1927 patients for analysis.
Measures
We measured RT receipt by asking: ‘‘Did you or are you
going to have radiation therapy to treat your breast can-
cer?’’ We also asked about the timing of treatment (com-
pleted, started, or planned), as well as whether initiation
of RT had been delayed for any reason. As noted above,
those who reported that they planned to receive RT but
had yet to start were excluded from analysis, so that the
self-reported measure of RT receipt in this study was con-
sidered positive only for patients who reported already
receiving radiation treatment.
We determined the final surgical procedure by ask-
ing about the initial surgical procedure after biopsy and
whether subsequent procedures were performed. We also
assessed age, race/ethnicity, comorbidities, insurance
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status at time of diagnosis, total household yearly income
at time of diagnosis, and educational attainment through
separate survey questions. For age and race/ethnicity, we
used SEER data for the few patients (<1%) missing data
by self-report. We used SEER data for clinical informa-
tion on tumor size and nodal status and to identify hospi-
tal of diagnosis, which we then categorized based upon
whether that hospital was accredited by the American
College of Surgeons.
To determine the RT receipt status in SEER registry
data, we used the radsum variable, which is used to indi-
cate any receipt of RT as part of initial therapy in the
SEER database. Those whom SEER coded as 0 (none) or
7 (refused) were coded as not receiving RT; those whom
SEER assigned codes 2 through 6 (codes for various
modalities of RT) were coded as receiving RT; the few
who were coded as 9 (unknown) and 8 (recommended;
unknown if given) were excluded from analysis as noted
above.
We defined underascertainment as patient report of
RT receipt among patients coded in SEER as not having
received RT.
Analysis
We compared self-reported data on RT receipt to RT as
reported in SEER registry records. We described the fre-
quency of RT underascertainment at each SEER site. We
then calculated rates of underascertainment at each site af-
ter grouping patients by clinical and sociodemographic
characteristics, as well as by treatment and hospital
characteristics.
We performed univariate analyses using chi-square
testing. We then regressed underascertainment within
each SEER site on stage, age, surgery type, race/ethnicity,
income, insurance, chemotherapy receipt, self-reported
delay of RT initiation, and American College of Surgeons
accreditation status of the diagnosing hospital as inde-
pendent variables, adjusting for clustering by hospital. We
evaluated all first-order interactions between significant
variables, and none was significant except as reported. All
results were weighted to account for the sampling design
and differential nonresponse. Results are presented as
unweighted values, with weighted percentages.
RESULTS
Table 1 compares the RT receipt code in SEER to patient
self-report. Of the 1292 patients who reported receiving
radiation, 273 were coded as not receiving RT in SEER
(underascertained). RT underascertainment was much
more common in Los Angeles than in Detroit (32.0% vs
11.25%, P< .001).
In Los Angeles, RT underascertainment was more
frequent in patients with higher stage, multiple comorbid-
ities, younger age, lower income, underinsurance, mastec-
tomy receipt, chemotherapy receipt, delayed initiation of
RT, and diagnosis at an American College of Surgeons
unaccredited hospital (Table 2). In Detroit, patients with
higher stage, mastectomy receipt, chemotherapy receipt,
and diagnosis at an unaccredited hospital were associated
with higher rates of RT underascertainment (Table 3).
On multivariate analysis, as shown in Table 4, RT
underascertainment was significantly associated in both
registries (P values for Los Angeles, Detroit) with stage (P
¼ .008, P ¼ .026), income (P < .001, P ¼ .050),
Table 1. SEER Registry Data Compared With Patient
Self-Report of RT Receipt
SEER Status Patient
Reports
RT Receipt
Patient
Reports No
RT Receipt
SEER Records RT Receipt 1019 (79%) 47 (7%)
SEER Records No RT Receipt 273 (21%) 588 (93%)
Total 1292 (100%) 635 (100%)
Abbreviations: RT, radiotherapy; SEER, Surveillance, Epidemiology, and
End Results.
Figure 1. Source of analyzed sample is shown. This flow dia-
gram details the way in which the analytic sample was devel-
oped. MD, medical doctor; RT, radiotherapy; SEER,
Surveillance, Epidemiology, and End Results.
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mastectomy receipt (P < .001, P < .001), chemotherapy
receipt (P < .001, P ¼ .045), and diagnosis at a hospital
that was not American College of Surgeons accredited (P
< .001, P < .001). In Los Angeles, additional significant
variables included younger age (P< .001), nonprivate in-
surance (P< .001), and delayed receipt of RT (P< .001).
DISCUSSION
The 2 SEER registries included in our study differed sub-
stantially in both rates and correlates of RT underascer-
tainment. RT underascertainment in Los Angeles was
nearly 3 higher than in Detroit and was associated with
age, insurance coverage, and delayed initiation of RT in
Table 2. Characteristics of Patients Who Reported RT Receipt and Rates of Underascertainment of
RT by the Los Angeles Surveillance, Epidemiology, and End Results Registry
Characteristic No. Weighted
%
% Underascertaineda Pb
Stage <.001
0 (DCIS) 135 22 26
I 290 48 26
II 139 21 42
III 70 9 47
Comorbidity .001
None 257 41 31
1 198 33 28
21 180 26 36
Age, years <.001
<50 165 22 43
50-64 263 43 32
651 207 34 23
Race .18
Black 162 12 33
White 184 65 29
Hispanic 283 21 33
Income <.001
<$20,000 130 13 34
$20,000-$69,999 234 37 38
$70,0001 129 30 27
Unknown 142 21 24
Insurance <.001
None 58 5 51
Medicaid 64 7 35
Medicare 149 26 27
Other 321 62 33
Unknown 58 5 51
Surgery type <.001
Breast conservation 548 87 28
Mastectomy 87 13 51
Receipt of chemotherapy <.001
Yes 260 35 45
No 369 65 24
Delay in initiating RT <.001
Yes 104 18 47
No 486 82 28
ACoS accreditation of diagnosing hospital <.001
Yes 234 41 27
No 387 59 33
Abbreviations: ACoS, American College of Surgeons; DCIS, ductal carcinoma in situ; RT, radiotherapy.
a Percentage underascertained calculated within the weighted sample.
bP values for differences in the proportion of RT receipt by the categories shown; separate category included for
‘‘unknown’’ when unknown values exceeded 5% (income).
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addition to variables that were significant at both locations
(stage, income, mastectomy receipt, chemotherapy
receipt, and hospital accreditation status). These results
suggest that SEER registry data, collected by routine
methods, may not be an appropriate source for docu-
menting rates of RT receipt by breast cancer patients or
for investigating geographic variation in RT receipt.
SEER data alone have long been used to evaluate the
appropriateness of breast cancer treatment, including RT
receipt. Nearly 2 decades ago, a seminal analysis of SEER
Table 3. Characteristics of Patients Who Reported RT Receipt and Rates of Underascertainment of
RT by the Detroit SEER Registry
Characteristic No. Weighted
%
% Underascertaineda Pb
Stage .02
0 (DCIS) 142 21 8
I 251 40 8
II 189 29 13
III 68 11 14
Comorbidity .14
None 245 39 13
1 202 31 8
21 210 31 11
Age, years .06
<50 162 25 14
50-64 309 47 10
651 186 28 9
Race .23
Black 178 19 8
White 446 76 12
Other or unknown 33 6 6
Income .53
<$20,000 87 12 11
$20,000-$69,999 266 40 12
$70,0001 198 32 9
Unknown 106 16 11
Insurance .50
None 10 2 0
Medicaid 36 5 10
Medicare 182 28 11
Other 420 66 11
Unknown 10 2
Surgery type <.001
Breast conservation 539 83 8
Mastectomy 111 17 25
Receipt of chemotherapy <.001
Yes 310 50 15
No 308 50 7
Delay in initiating RT .91
Yes 113 18 11
No 507 82 11
ACoS accreditation of diagnosing hospital <.001
Yes 424 68 9
No 201 32 16
Abbreviations: ACoS, American College of Surgeons; DCIS, ductal carcinoma in situ; RT, radiotherapy.
a Percentage underascertained calculated within the weighted sample.
bP values for differences in the proportion of RT receipt by the categories shown; separate category included for
‘‘unknown’’ when unknown values exceeded 5% (income).
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data from 1983 to 1986 documented rates of RT receipt
after BCS that varied significantly by geography, race, and
age.3 Another landmark study of SEER data from 1983 to
19954 found a decrease in the use of appropriate primary
therapy for early stage breast cancer over time (with only
78% of women receiving appropriate primary therapy in
1995), driven by an apparent increase in use of BCS that
was not followed by RT or axillary surgery.
However, several studies have since raised questions
about the completeness of registry data, especially for
treatments such as RT, which are often delivered in the
outpatient setting. Bickell and Chassin took data collected
as part of a quality improvement project on 365 cases of
stage I-II breast cancer diagnosed between 1994 and 1996
at 3 New York hospitals and compared them with data in
the hospitals’ tumor registries, finding that only 58% of
Table 4. Logistic Regression Models of RT Underascertainment
Characteristic Los Angeles Detroit
Odds
Ratio
95%
Confidence
Interval
Pa Odds
Ratio
95%
Confidence
Interval
Pa
Stage .008 .026
0 1.00 1.00
I 0.82 0.64 1.03 0.67 0.35 1.28
II 1.32 0.94 1.83 0.69 0.30 1.56
III 0.76 0.49 1.21 0.26 0.09 0.70
Age, years <.001 .36
<50 3.01 2.09 4.31 1.34 0.54 3.30
50-64 1.91 1.38 2.66 0.95 0.42 2.16
651 1.00 1.00
Race .14 .13
White 1.00 1.00
Black 0.84 0.63 1.12 0.57 0.32 1.04
Hispanicb 0.78 0.61 0.99
Other 0.59 0.2 1.71
Income <.001 .050
<$20,000 1.12 0.79 1.60 1.15 0.48 2.71
$20,000-$69,999 1.66 1.31 2.11 1.96 1.19 3.24
$70,0001 1.00 1.00
Unknown 1.02 0.76 1.37 1.42 0.72 2.78
Insurance <.001 .87
None 1.94 1.23 3.05 <0.001 <0.001 >999
Medicaid 1.26 0.86 1.87 0.82 0.31 2.17
Medicare 2.19 1.60 3.00 0.70 0.30 1.67
Other 1.00 1.00
Surgery type <.001 <.001
Breast conservation 1.00 1.00
Mastectomy 2.07 1.50 2.85 4.93 2.84 8.57
Chemotherapy receipt <.001 .045
Yes 1.84 1.43 2.37 1.86 1.02 3.41
No 1.00 1.00
Delay initiating RT <.001 .15
Yes 1.93 1.52 2.44 0.66 0.38 1.16
No 1.00 1.00
Diagnosed at ACoS accredited hospital <.001 <.001
Yes 1.00 1.00
No 1.30 1.10 1.55 2.05 1.40 3.00
Abbreviations: ACoS, American College of Surgeons; RT, radiotherapy.
aP values for group variables are reported from Wald tests; standard errors were adjusted for hospital clustering.
b There were too few Hispanic patients in Detroit to support a separate category. Thus, Hispanics in Detroit were included in the ‘‘other’’ race category.
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RT was captured by the registries.6 Malin et al compared
California Cancer Registry data with data abstracted from
medical records of 304 patients in the PacifiCare of Cali-
fornia health plan who were diagnosed with breast cancer
from 1993 to 1995 in Los Angeles; they found that only
72.2% of RT was captured by the registry.7 Given the
sample size and the finding that studied patients were
older and less diverse than the Los Angeles population,
the study’s ability to detect sociodemographic differences
was limited. Systematic differences in ascertainment by
disease stage were observed, however, and the authors
noted that patients with more advanced disease more of-
ten received treatment in the ambulatory setting that was
less likely to be reported to the registry.
Despite these studies, researchers have continued to
use SEER data for evaluation of RT receipt. For example,
a study published this year used SEER data to study rates
of RT receipt among patients with locally advanced breast
cancer, by race and surgery type.8 The authors concluded
that ‘‘rates of RT were low for all populations’’; although
they considered several possible explanations for this find-
ing, they did not mention the possibility of RT underas-
certainment. They did state, ‘We considered RT use as a
single surrogate marker of quality cancer care, but there
are certainly others. Rates of breast reconstruction and ad-
herence to hormonal or systemic therapy guidelines are all
potential surrogate markers of quality cancer care, but
these data fields are either limited or unavailable in the
SEER database.’’ However, they did not consider the pos-
sibility that the RT field in the SEER database might also
have limitations. Ironically, in their introduction, the
authors cited Malin’s study, but only in support of the
statement, ‘‘Adherence to RT guidelines improves overall
and disease-specific survival and has been used as a surro-
gate marker of quality BCa care.’’
Other recent studies have acknowledged concerns
about limitations of SEER registry data but have dis-
missed these largely based upon comparisons to merged
SEER-Medicare data. For example, when Du and Gor
published an analysis of RT receipt based on SEER data
from 1992 to 2002,10 they referenced a study using
merged SEER-Medicare data on women aged 65 to 74
years diagnosed with breast cancer in 1992, finding that
among 2784 women whom SEER recorded as not receiv-
ing RT, Medicare identified only 377 (13.5%) as receiv-
ing RT.17 They also referenced a study18 of SEER-
Medicare data from 1991 to 1996 in patients 65 and older
that found 94% agreement between SEER and SEER-
Medicare for RT receipt in breast cancer patients, with
only minimal variation between individual SEER regis-
tries. Similarly, when Freedman and colleagues conducted
a study using SEER data from 1988 to 2004, they
included an appendix assessing RT underascertainment
using the SEER-Medicare dataset from 1992 to 2002.9
They found 91% agreement between the 2 data sources
and concluded that ‘‘it is unlikely that our findings would
be explained by problems ascertaining radiation therapy
by the SEER registries.’’ Sufficiently reassured to consider
SEER data alone, they found a decrease in RT after BCS
from 79% in 1988 to 66% in 2004, with differences by
race, SEER site, and age. These rates are markedly lower
than those reported by our patients in Los Angeles and
Detroit in 2006.19
More recently, Dragun and colleagues published an
interesting analysis that documented a 66% overall rate of
radiation receipt, and significantly lower receipt in rural/
Appalachian populations, in the Kentucky Cancer Regis-
try (KCR).20 These researchers discussed potential limita-
tions in registry data but noted that the KCR ‘‘has been
awarded the highest level of certification by the North
American Association of Central Cancer Registries for an
objective evaluation of completeness, accuracy, and time-
liness every year since 1997. The KCR is also part of the
. . . SEER program, which has the most accurate and
complete population-based cancer registry in the world.’’
Unfortunately, North American Association of Central
Cancer Registries accreditation does not consider accuracy
of coding of treatment receipt, including radiation
receipt; it only confirms that there is accuracy, complete-
ness, and timeliness with respect to identification of inci-
dent cases of cancer and demographic characteristics.21
Thus, although the study findings may well reflect a true
problem with undertreatment in settings where health
care facilities are more limited, one must exercise caution
in drawing firm conclusions unless treatment information
in the Kentucky registry has been validated in ways not
discussed in that article, as RT underascertainment may
also be more likely in such settings.
Of note, the current study shows that RT underas-
certainment appears to be more frequent among younger
patients not represented in SEER-Medicare comparisons
and can occur even in SEER registries holding North
American Association of Central Cancer Registries ac-
creditation for high-quality incident case ascertainment.
Moreover, more breast cancer patients receive chemother-
apy before RT today than in the time periods of studies
comparing SEER to SEER-Medicare data. Although the
first course of treatment is no longer defined by SEER as a
Underascertainment of RT by SEER/Jagsi et al
Cancer January 15, 2012 339
4-month period from diagnosis, increased time between
diagnosis and RT because of the administration of chemo-
therapy increases the difficulty for registrars to ascertain
radiation receipt. In light of the findings of our current
study, showing substantial RT underascertainment in 1
of the largest SEER registries, we believe that future stud-
ies should not use the SEER dataset alone to determine
rates or correlates of RT receipt until the quality of the
data in the other SEER registries are investigated more
closely.
Of note, SEER itself recognizes the limitations in
registry data collected by routine methods and so regularly
also conducts Patterns of Care studies focused on different
cancer sites.22,23 These studies involve reabstraction
of treatment information from hospital records and
requests to physician offices to capture therapy adminis-
tered in the outpatient setting. Additional analysis
using these methods would be valuable to assess rates of
RT underascertainment in other registry sites before fur-
ther research relies upon SEER data alone to assess RT
receipt. Certainly, the findings of the current study are
sobering.
The substantial differences in rates of ascertainment
by the 2 registries likely reflect differences in the methods
of surveillance. In the Detroit registry, surveillance is
active, and radiation facilities are surveyed as part of the
process of incident case identification, which also allows
for updating of the radiation receipt variable. In the Los
Angeles registry, where surveillance depends upon report-
ing by registrars, it is not surprising that rates of RT under-
ascertainment are higher. Reporting of treatment received
in the outpatient setting is particularly difficult for regis-
trars to capture. Moreover, in California, the state law that
established the registry system does not require capture of
treatment given outside the reporting facility. Thus, it is
not surprising that RT underascertainment is strongly
associated with hospital accreditation status, as American
College of Surgeons-accredited cancer programs are
required to capture all first-course treatments regardless of
location, in contrast to the more basic requirements of
state law that govern other institutions. The independent
association of numerous clinical and sociodemographic
variables with ascertainment likely reflects the way in
which differences in these factors affect the timing of care
and the type and/or number of facilities within which these
patients receive medical care.
This study has several strengths, including its large
sample size and diverse population. It also has several
potential limitations. First, it relied upon self-report as the
gold standard to which SEER data were compared.
Although we recognize that there is no true gold standard,
previous studies have supported the validity of self-report
regarding RT and have documented very high correlations
between self-report and medical record review.24-26 Crite-
rion validity is supported by the finding that the over-
whelming majority of patients who reported receiving
radiation went on to respond that they had received infor-
mation regarding management of RT side effects and
reported receiving 5 weeks of treatment, as well as the
finding that self-reported receipt of radiation was highly
correlated with clinical factors that direct treatment
recommendations.
Second, although this is the first study to our knowl-
edge of RT underascertainment, other than the SEER-
Medicare studies, to include >1 geographic location, the
study was limited to 2 metropolitan SEER registries. It is
therefore not possible to comment definitively upon
the rates of RT underascertainment in other registries, par-
ticularly more rural registries. Nevertheless, these data are
sufficient to conclude that RT underascertainment is not
uniform across SEER sites and can be quite substantial.
The call for comparative effectiveness research has
led to heightened interest in the analysis of population-
based registry data. As increasing numbers of researchers
begin to use registry data, it is critical to evaluate the qual-
ity of those data. The SEER regional registry network rep-
resents a golden opportunity to continue to build
population-based translational cancer research with real
value to patients and their clinicians. Indeed, recent
changes and additions to the content of SEER data reflect
the increasing complexity of clinical information and
treatment modalities for cancer and the interest of stake-
holders in enhancing the use of these data for the purpose
of assessing quality of care and outcomes.27 However,
increased demand for breadth and depth of data against
decreasing budgets for its collection may be counterpro-
ductive. This study provides only 1 example of the ways in
which misuse of poor quality data may lead to spurious
policy conclusions. One increasingly common strategy to
improve data quality is for registries to partner with inves-
tigators to use supplemental research funding for special
studies in cancer outcomes and effectiveness research.
Another strategy might be to allow and encourage re-
gional SEER registries to subspecialize in the collection of
the more challenging and resource-intensive data elements
related to the first course of therapy. This would create re-
gional registries of excellence with particular strengths in
certain cancers or treatment modalities. The increasing
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complexity of cancer care and increasing demand to evalu-
ate it motivate researchers to find creative solutions to
ensure the highest validity and quality of data collected by
regional cancer registries.
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